Lawood & Co. Cuts Stock Holdings in AbbVie Inc. $ABBV

Lawood & Co. lowered its stake in AbbVie Inc. (NYSE:ABBV) by 15.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,978 shares of the company’s stock after selling 2,245 shares during the period. AbbVie makes up approximately 1.9% of Lawood & Co.’s holdings, making the stock its 16th biggest position. Lawood & Co.’s holdings in AbbVie were worth $3,133,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Burk Holdings LLC acquired a new stake in AbbVie in the 2nd quarter worth approximately $30,000. Marquette Asset Management LLC raised its position in shares of AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. Abound Financial LLC acquired a new stake in shares of AbbVie in the fourth quarter worth $32,000. Principia Wealth Advisory LLC lifted its stake in shares of AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock worth $40,000 after buying an additional 44 shares during the last quarter. Finally, Merkkuri Wealth Advisors LLC bought a new stake in shares of AbbVie during the 1st quarter worth $34,000. Institutional investors own 70.23% of the company’s stock.

Insider Activity at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the completion of the transaction, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ABBV. UBS Group lifted their target price on shares of AbbVie from $260.00 to $275.00 and gave the stock a “neutral” rating in a report on Tuesday. Bank of America reiterated a “buy” rating on shares of AbbVie in a research note on Tuesday, September 8th. Rothschild & Co Redburn boosted their price objective on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Leerink Partners increased their target price on AbbVie from $245.00 to $279.00 and gave the company an “outperform” rating in a research note on Wednesday, August 5th. Finally, Argus lifted their price target on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $277.18.

AbbVie Stock Performance

Shares of ABBV traded up $5.14 during trading hours on Friday, reaching $277.56. 1,204,165 shares of the company traded hands, compared to its average volume of 6,402,646. The stock’s fifty day moving average is $258.56 and its 200 day moving average is $236.35. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $277.45. The stock has a market cap of $490.40 billion, a P/E ratio of 78.36, a price-to-earnings-growth ratio of 1.23 and a beta of 0.24.

AbbVie (NYSE:ABBV) last released its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.80 billion. During the same period last year, the business earned $2.97 earnings per share. The firm’s revenue for the quarter was up 10.2% compared to the same quarter last year. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, equities research analysts predict that AbbVie Inc. will post 14.01 EPS for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.5%. AbbVie’s payout ratio is currently 195.48%.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts raise targets and maintain bullish ratings: Guggenheim reaffirmed its “buy” rating with a $288 price target, while JPMorgan raised its target to $300 and kept an “overweight” rating. Cantor Fitzgerald also lifted its target to $290 and maintained “overweight.” These actions signal that analysts see further upside for ABBV. AbbVie Shares Up After Analyst Upgrade
• Positive Sentiment: Temab-A receives two FDA Breakthrough Therapy designations: AbbVie’s telisotuzumab adizutecan, also known as Temab-A, received designations for colorectal cancer and non-small cell lung cancer. The regulatory recognition could accelerate development and review, strengthening expectations for the company’s oncology pipeline. FDA Grants Breakthrough Therapy Designations to AbbVie’s Temab-A
• Positive Sentiment: Momentum and investor interest remain elevated: AbbVie reached a new one-year high following the analyst upgrade, reinforcing the market’s favorable reaction to the target increases and pipeline developments. AbbVie Reaches a New 52-Week High
• Neutral Sentiment: Breakthrough status is not approval: The FDA designations may speed development, but Temab-A still faces clinical, regulatory and commercial risks before it can generate revenue.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.